Market research
ACIU AC Immune Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 288M
- P/E ratio
- Not available
- Analyst target
- 8.6113
- Dividend yield
- Not available
- Beta
- 1.57
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CH0329023102
- Market cap
- 288M
- P/E ratio
- Not available
- Analyst target
- 8.6113
- Dividend yield
- Not available
- Beta
- 1.57
About
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ACIU discussion.
5 years, 4 months ago
AC Immune SA is currently in a long term uptrend where the price is trading 23.3% above its 200 day moving average.
From a valuation standpoint, the stock is 97.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 33.8.
AC Immune SA's total revenue sank by 11.1% to $944K since the same quarter in the previous year.
Its net income has dropped by 0.3% to $-20M since the same quarter in the previous year.
Finally, its free cash flow fell by 51.9% to $-20M since the same quarter in the previous year.
Based on the above factors, AC Immune SA gets an overall score of 2/5.